TRU-D SmartUVC LLC, producers of the first and only automated, no-touch UV disinfection robot, announces that the General Services Administration has awarded the company a GSA Schedule contract through November 2019.
This newly formed agreement will allow TRU-D SmartUVC LLC to rapidly engage all levels of government purchasers, including Department of Veteran Affairs and Department of Defense medical facilities, as well as Homeland Security contacts purchasing solutions for the Ebola effort in West Africa. In addition to hundreds of health care facilities in the United States, Canada, and Europe that have deployed TRU-D, two devices were deployed earlier this year in Liberia to combat Ebola. They operate daily in Liberian Ebola Treatment Units to assist and protect health care workers and patients in the fight against the deadly virus.
"Securing this GSA contract is important to increasing access to TRU-D SmartUVC for the government sector, as we fulfill the demand for our innovative technology in these medical facilities," says Chuck Dunn, president and Efficer of TRU-D SmartUVC LLC. "Just as we've had success with private and public health care systems, we are eager to expand our broad placements in VA medical centers and continue to make a positive impact in the infection control initiatives of government facilities in the United States and internationally."
Validated by 10 independent studies and proven to kill nearly 100 percent of pathogens, TRU-D is simple to set up and does not require input of room measurements or covering of windows and vents. TRU-D precisely calculates the time necessary to deliver a guaranteed dose of germ-eliminating UV light energy and records that usage information to report to infection prevention teams, capabilities no other device on the market has.
TRU-D SmartUVC is the device of choice for nearly all of the existing independent research on UV disinfection technology. Hundreds of TRU-Ds have been deployed to disinfect hospitals across the U.S., Canada, Europe and Africa, including the National Institutes of Health Clinical Center in Bethesda, Maryland; the Ralph H. Johnson VA Medical Center in Charleston, South Carolina; and Houston Methodist in Houston, Texas.